Roivant Sciences Ltd. Common Shares
Market Cap
20B
Short interest (May 15)
3.8%
Net Short (Jun 03 ): 0.0%
Borrow Fee
0.25%
↑ 2.0%
Available Shares
10M
↑ 8.1%
Price Chart
Company Overview
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.